PODD

Insulet Corporation

Healthcare
148.14 down -0.24 -0.16% Pre-Market
2026-09-02 • USD

Key Metrics

Market Cap 10.27B
EV 10.69B
Shares Out 69.35M
Revenue (ttm) 3.05B
Net Income 375.30M
Beta
P/E
Forward P/E
EPS (ttm) $5.33
P/S 3.36
P/B 7.22
P/FCF 34.95
P/C 20.08
EV/Sales 3.50
EV/EBITDA 17.50
ROA 12.12%
ROE 26.75%
ROIC 16.5%
Gross Margin 71.08%
Oper. Margin 16.89%
Profit Margin 12.29%
Debt/Eq 0.67
LT Debt/Cap 39.52%
Quick Ratio 1.51
Current Ratio 2.48
Book/sh 20.52
Cash/sh 7.72
Div Yield
Div TTM
Payout Ratio
SMA20 2.07%
SMA50 -4.06%
SMA200 -30.13%
Volume 1,113,956
Avg Volume 1.68M
Rel Volume 0.66
Perf Week 3.47%
Perf Month -12.56%
Perf Quarter 3.55%
Perf Half Y -38.65%
Perf YTD -47.80%
Perf Year -56.81%
Perf 3Y -22.79%
Perf 5Y -50.96%

Factor Lens

Seasonal Performance

Financial Trends

Revenue & Net Income

Earnings Per Share

Margins

Cash Flow

Company Overview

Insulet Corporation is primarily engaged in the development, manufacture, and sale of proprietary continuous insulin delivery systems for people with insulin-dependent diabetes.

Name
Insulet Corporation
Industry
Medical Devices
CEO
Ashley A. McEvoy · President and Chief Executive Officer
Employees
IPO Date
2015-05-04
Phone
(978) 600-7000
Address
100 Nagog Park, Acton, MA 01720
Website

Key Executives

Name Title FY Pay
Wayne A. I. Frederick Interim President, Howard University
Timothy C. Stonesifer Chief Financial Officer, Alcon Inc.
Michael R. Minogue President and Chief Executive Officer, Minogue Consulting, LLC
Luciana Borio Venture Partner, ARCH Venture Partners
Ashley A. McEvoy President and Chief Executive Officer

Latest News